BeOne Medicines Ltd. – Sponsored ADR $ONC Holdings Raised by AIA Group Ltd

AIA Group Ltd increased its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 31.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,303 shares of the company’s stock after buying an additional 7,716 shares during the quarter. AIA Group Ltd’s holdings in BeOne Medicines were worth $11,006,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Coldstream Capital Management Inc. acquired a new position in BeOne Medicines during the 3rd quarter valued at about $201,000. NewEdge Advisors LLC lifted its stake in shares of BeOne Medicines by 19.6% in the 3rd quarter. NewEdge Advisors LLC now owns 1,856 shares of the company’s stock worth $632,000 after acquiring an additional 304 shares during the period. Voloridge Investment Management LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter worth approximately $16,270,000. Nomura Holdings Inc. bought a new position in shares of BeOne Medicines in the third quarter valued at approximately $12,606,000. Finally, Mariner LLC bought a new position in shares of BeOne Medicines in the third quarter valued at approximately $290,000. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a report on Monday, January 12th. Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the company from $420.00 to $290.00 in a research note on Monday. Truist Financial lifted their price target on BeOne Medicines from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Royal Bank Of Canada boosted their price objective on BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen cut BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $389.18.

Insider Buying and Selling at BeOne Medicines

In other news, SVP Chan Henry Lee sold 341 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders sold 2,665 shares of company stock worth $902,792. Company insiders own 6.62% of the company’s stock.

BeOne Medicines Stock Down 1.8%

NASDAQ ONC opened at $282.29 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $196.45 and a 12 month high of $385.22. The company has a market capitalization of $30.96 billion, a P/E ratio of 112.02 and a beta of 0.53. The company’s 50 day simple moving average is $332.21 and its 200 day simple moving average is $329.38. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.